Immunocore Holdings plc Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement2019
Immunocore Holdings plc (IMCR) reported Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement2019 of $57.51 per share for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 · last filed 2023-08-10
- Immunocore Holdings plc weighted average exercise price of share options exercised in share-based payment arrangement2019 for the quarter ending 2023-06-30 was $57.51, a 99.27% increase year-over-year.
- Immunocore Holdings plc weighted average exercise price of share options exercised in share-based payment arrangement2019 for the quarter ending 2022-09-30 was $37.25, a 4.54% decline year-over-year.
- Immunocore Holdings plc weighted average exercise price of share options exercised in share-based payment arrangement2019 for the quarter ending 2022-06-30 was $28.86.
- Immunocore Holdings plc weighted average exercise price of share options exercised in share-based payment arrangement2019 for the quarter ending 2021-09-30 was $39.02.
| Period end | Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement2019 3 month | Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement2019 6 month | Weighted Average Exercise Price Of Share Options Exercised In Share-based Payment Arrangement2019 9 month |
|---|---|---|---|
| 2023-06-30 | $57.51 6-K · filed 2023-08-10 | $63.94 6-K · filed 2023-08-10 | |
| 2022-09-30 | $37.25 6-K/A · filed 2022-11-18 | $25.49 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | $28.86 6-K · filed 2023-08-10 | $25.47 6-K · filed 2023-08-10 | |
| 2021-09-30 | $39.02 6-K/A · filed 2022-11-18 | $26.19 6-K/A · filed 2022-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |